Is Now a Good Time to Buy Cardinal Health Stock?

NYSE: CAH | Cardinal Health Inc. News, Ratings, and Charts

CAH – Cardinal Health (CAH) has not only managed to stay afloat amid much market uncertainty but reported revenue growth across its segments in its last-reported quarter. So, I think it is wise to bet on the stock now because it is trading at a discount to its peers and could generate healthy ROI in the near term.

In business for more than four decades, the health services and products company Cardinal Health, Inc. (CAH) has advanced  23.4% over the past 10 years to close Friday’s trading session at $52. Moreover, CAH’s revenue has increased at a CAGR of 5.7% over the past three years.

Because the ongoing COVID-19 mass vaccination drive is making people reconsider visiting hospitals to undergo postponed surgeries for non-COVID-19 related health issues, the company is expected to witness an increase in demand for its offerings, such as surgical, and laboratory products, and single-use surgical drapes. With the increase in the number of hospital visits for non-COVID matters, the company is expected to witness increased demand for its products including medical gowns and apparel, and operating room supplies.

CAH is strategically positioned to gain both amid the pandemic and in the post-pandemic era. For instance, the company was selected by the Ohio Department of Health in December 2020 to support its efforts to distribute COVID-19 vaccines by arranging transportation within the state. CAH also reached an agreement with the Centers for Disease Control and Prevention (CDC) in November 2020 to act as a network administrator in Phase 2 of the Federal Pharmacy Partnership Strategy for COVID-19.

Here what I think could shape CAH’s performance:

Discounted Valuation

In terms of non-GAAP forward p/e, the stock is trading at 8.55x, which is significantly lower than the industry average 24.78x. Also, CAH’s forward ev/s of 0.11x is much lower than the industry average 8.94x. And in terms of forward p/s, the stock’s 0.09x is much lower than the industry average  9.77x.

Impressive Recent Financials

CAH’s  revenue climbed 6.3% sequentially to $41.54 billion for the fiscal 2021 second quarter, ended December 31, 2021. Its revenue from the Pharmaceutical segment increased 4.5% year-over-year to $37.24 billion over the same period, driven primarily by sales growth from Pharmaceutical Distribution and Specialty Solutions customers. Moreover, CAH’s revenue from the Medical segment increased more than 7% to $4.31 billion. It was mainly driven by a net positive impact from COVID-19, specifically  the impact of personal protective equipment (PPE) sales and higher volumes in the company’s lab business.

Over the same period, CAH’s net earnings increased 185.9% year-over-year to $629 million and its non-GAAP EPS increased 14.5% year-over-year to $1.74. The company has also surpassed consensus EPS estimates in each of the trailing four quarters.

Favorable Analyst Estimates

Analysts expect the company’s revenue to increase 10.3% for the quarter ending June 30, 2021. Its EPS is expected to grow 16.3% for the quarter ending June 30, 2021, 10.3% in fiscal 2021 and at a rate of 7.6% per annum over the next five years.

CAH has an average broker rating of 1.75, which indicates favorable analyst sentiment. Wall Street analysts expect the stock to hit $63.06 in the near term, which indicates a potential upside of 22.8%.

POWR Ratings Indicate Solid Prospects

CAH has an overall rating of B, which equates to Buy in our POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors with each factor weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight different categories. The stock has a grade of A for Value, consistent with discounted valuation.

CAH has a grade of B for growth, in sync with the expected increase in revenue and EPS. CAH has a grade of B for Stability as well.

The stock is rated for Momentum, Sentiment and Quality as well. Get all CAH’s ratings here.

CAH is ranked #5 of 77 stocks in the Medical – Services industry.

Click here to access several other top-rated stocks in the same industry.

Bottom Line

We think CAH’s strong fundamentals and market dominance should drive the performance of the stock. Also,  the stock is also trading at a discount now, so it might have plenty of upside left because  demand for its products and services is expected to increase in the coming months.

Want More Great Investing Ideas?

“MUST OWN” Growth Stocks for 2021

How to Ride the 2021 Stock Market Bubble

7 Best ETFs for the NEXT Bull Market

5 WINNING Stocks Chart Patterns


CAH shares were trading at $51.93 per share on Monday morning, down $0.07 (-0.13%). Year-to-date, CAH has declined -3.04%, versus a 3.78% rise in the benchmark S&P 500 index during the same period.


About the Author: Manisha Chatterjee


Since she was young, Manisha has had a strong interest in the stock market. She majored in Economics in college and has a passion for writing, which has led to her career as a research analyst. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CAHGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

3 Energy Stocks Set to Soar Beyond Expectations

Given the geopolitical tensions, increasing global oil demand, and supply adjustments, the energy sector is poised for robust growth. Therefore, investors might consider investing in energy stocks TechnipFMC (FTI), Weatherford International (WFRD), and ChampionX (CHX), which are poised to exceed expectations. Keep reading…

Has Carnival (CCL) Stock Turned Into a Buy After Earnings Release?

Carnival Corporation (CCL) reported record revenue in its most recent quarter but still faces a negative bottom line. The collapse of Francis Scott Key Bridge brings more uncertainty to its financials. Given these events, what stance should one take with CCL stock? Read more to find out…

3 China Stocks Positioned for Long-Term Growth

Despite facing challenges, the Chinese economy has demonstrated resilience, as evidenced by recent robust industrial output and retail sales data. Given this outlook, it might be an opportune time to own three top-notch China stocks, JD.com, Inc. (JD), China Automotive Systems (CAAS), and Youdao, Inc. (DAO). Read on…

What Data Should Investors Focus on Now?

The S&P 500 (SPY) is up nearly 50% from the bear market lows. That is a sign the easy money has been made. The next likely catalyst for stocks will probably be the first Fed rate cut...but maybe that is really the final push before a long overdue sell off? Tune in to discover what investment veteran Steve Reitmeister has to say about the market outlook along with his trading plan and top picks to stay ahead of the pack. Read on below for more...

Read More Stories

More Cardinal Health Inc. (CAH) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CAH News